๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Abdominovaginal potential difference in postmenopausal patients with and without breast cancer

โœ Scribed by Henry M. Lemon; Langdon Parsons; Peter H. Mozden


Publisher
John Wiley and Sons
Year
1964
Tongue
English
Weight
913 KB
Volume
17
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

โœฆ Synopsis


HE EXISTENCE OF ELECTRIC POTENTIAL DIF-

T ferences between human vaginal mucosa and a reference point on the anterior abdominal wall has been known for several decades. Early investigations correlated changes in potential difference between these sites with ovulation and menstruation in several species.3~ 6. 13 The use of silver-silver chloride electrodes in early studies may have led to erratic results, since these readily give rise to artefacts if the silver chloride plating is faulty, and, like other metallic electrodes, respond to changes in hydrogen ion concentration of their environment.21 Recently, an improved method of measuring bioelectric potentials from epithelial surfaces has been described, utilizing a prototype model high-impedance vacuum tube recording milliepotentiometer, connected through balanced calomel half cells to liquid electrodes with minimal resistance.11 The electrodes that are used consist of 0.85y0 sodium chloride-agar in glass tubes of at least 5 mm. internal diameter that are occluded distally by the patient's skin (abdominal reference electrode) or by a moist cotton plug that is placed in contact with the vaginal mucosa.

This report concerns observations of a series of pre-and postmenopausal patients with benign diseases and a group, largely postmenopausal, with mammary cancer. It was From the Eugene C.


๐Ÿ“œ SIMILAR VOLUMES


Variations in locoregional therapy in po
โœ J. G. H. van Nes; C. Seynaeve; S. Jones; C. Markopoulos; H. Putter; Professor C. ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 130 KB

## Abstract ## Background The Tamoxifen and Exemestane Adjuvant Multinational (TEAM) trial is an international randomized trial evaluating the efficacy and safety of exemestane, alone or following tamoxifen. The large number of patients already recruited offered the opportunity to explore locoregi

Fadrozole hydrochloride in postmenopausa
โœ Antonius A. Miller; Allan Lipton; I. Craig Henderson; Rudolph Navari; Mary T. Mu ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 471 KB ๐Ÿ‘ 2 views

## BACKGROUND. Fadrozole hydrochloride (CGS-16949A) belongs to the class of aromatase inhibitors that lowers circulating estrogen levels by inhibiting the conversion of androgens to estrogens, thereby causing tumor regression in patients with breast carcinoma. METHODS. This was a prospective, ran